DGAP-Adhoc: MOLOGEN AG resolves capital increase from

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Feb 5, 2014 at 4:00 PM

DGAP-Adhoc: MOLOGEN AG resolves capital increase from authorized capital

MOLOGEN AG / Key word(s): Capital Increase 05.02.2014 21:47 Dissemination of an Ad hoc announcement according to Â§ 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- With the approval of the Supervisory Board and on the basis of the registered authorized capital the Management Board of MOLOGEN AG decided today to increase the share capital against cash contributions without subscription rights of the shareholders from currently EUR 15,419,512 to EUR 16,960,756 Euros by issuing up to 1,541,244 new no-par value bearer shares with dividend rights from 1st January 2013. The proceeds from the capital increase will be used to further strengthen the equity base and in particular to finance the development of the product pipeline and the necessary ongoing research operations. The new shares will be offered to European qualified investors in the context of a private placement. The placement starts today, 5 February 2014, and is expected to be completed tomorrow, 6 February 2014. MOLOGEN AG will set the issue price after the completion of a bookbuilding process and depending on the market situation at a discount of up to 5 per cent on the volume weighted average share price in Xetra trading during the last five trading days or on the in XETRA trading lastly determined stock price. The new shares shall be admitted to trading, without prospectus requirement, in the sub-segment of the regulated market with further post-admission obligations (Prime Standard) of the Frankfurt Stock Exchange. --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: DISCLAIMER This document is not an offer of securities for sale in the United States of America. The securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the 'Securities Act') and may not be offered or sold absent registration or an exemption from registration under the Securities Act. The Issuer does not intend to register any portion of the offering in the United States of America or to conduct a public offering of the securities in the United States of America, Canada, Australia, Japan or South Africa. About MOLOGEN AG MOLOGEN AG is a publicly listed biotechnology company headquartered in Berlin and specializes in the research and clinical development of innovative drugs in the fields of oncology and infectious diseases. One of the company's most important product candidates is the DNA immunomodulator MGN1703, which is being clinically developed for colorectal cancer and lung cancer. The cell-based cancer therapy MGN1601 for the treatment of renal cancer is also currently at the stage of clinical development.â?¨â?¨With unique, patented technologies and innovative product developments, MOLOGEN is one of the leading biotechnology companies in the fields of DNA medicine and cell-based therapies.â?¨â?¨MOLOGEN AG shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com Memberships in associations: Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI) MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. MOLOGEN AG PRESS SERVICE: Prof. Peter W. HÃ¼bner Head of Corporate Communications Tel: +49 - 30 - 84 17 88 - 38 Fax: +49 - 30 - 84 17 88 - 50 huebner@mologen.com INVESTOR RELATIONS: JÃ¶rg PetraÃ? Tel: +49 - 30 - 84 17 88 - 13 Fax: +49 - 30 - 84 17 88 - 50 investor@mologen.com External Investor Relations: Kirchhoff Consult AG Sebastian Bucher Tel: +49 - 40 - 60 91 86 - 18 Fax: +49 - 40 - 60 91 86 - 16 sebastian.bucher@kirchhoff.de 05.02.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: MOLOGEN AG FabeckstraÃ?e 30 14195 Berlin Germany Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: info@mologen.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, DÃ¼sseldorf, Hamburg, MÃ¼nchen, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Eric Dalton: Redefining Homecare with Vision and Strategy

What's Behind Eric Dalton's Continued Recognition? Now, if you told me a healthcare leader’s named 'Visionary of the Year' twice in a row, my first thought isn't 'stretch goals' but 'show me the goods.' And that’s precisely what Eric J. Dalton has done. The Vice President at Angels on Call Homecare isn't just tooting his own horn; he's building a damn symphony in the...

LG Energy Sparks Global Innovation with BIC 2026

Innovating Beyond Boundaries with LG Energy The world of battery tech is on fire, and LG Energy Solution is fanning the flames with their Battery Innovation Contest 2026 (BIC 2026). From October 29 to December 6, 2026, universities and research hives across the globe are being beckoned to pour their battery brilliance into this contest. These aren't just any research...

Clip Expands Horizons with Pulpos Acquisition, New Board Member

Clip's Strategic Move with Pulpos Clip just laid down a serious marker in the digital payment world by snagging Pulpos, a firm that’s got its claws deep into AI-driven business management software. This move isn't just some fancy headline. It's a real, grounded step in expanding Clip's ecosystem to bolster the backbone of Mexico's economy: small and medium-sized...

Genefluence Launches Rapid UTI PCR Test at Chelsea Hospital

There's a fresh breeze blowing through the dusty corridors of healthcare, shaking things up for the better. You see, Genefluence, the brainchild of Professor Chris Toumazou, isn't just throwing a bunch of tech jargon around—it's setting the stage for a much-needed shake-up in how we handle urinary tract infections (UTIs) and, believe me, it couldn’t have come sooner....

Honeywell Aerospace Posts Solid Q3, Raises Guidance

Honeywell Aerospace Surprises with Strong Third Quarter In a world where numbers are often as slippery as a greased pig, Honeywell Aerospace (NASDAQ:HONA) has managed to pin down a surprisingly robust third quarter. Let’s break it down: they’ve claimed sales of a cool $4.6 billion, reflecting a 2% bump both in reported and organic revenue from the previous year, and...

Oracle's Bold Vision: Targeting $225B Revenue by 2030

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

2026 Global Ocean Forum Unveils Key Marine Strategies

Riding the Waves in Qingdao It ain't every day that a talk-fest dedicated to oceans gets my attention, but when the Global Ocean Development Forum plants its flag in Qingdao, even I sit up. We're talking about some real fireworks in the marine economy sector with this gig's '1+1+4+8' framework. Now, before you scratch your head on the bingo numbers—it's the opening...

TransCode Pursues Strategic Moves for TTX-MC138 Value

A New Chapter for TransCode? Every once in a while, you find companies taking bold steps that make the market look twice. Today, that’s TransCode Therapeutics (NASDAQ: RNAZ) putting their chips on the table, determined to find the best route forward for their oncology efforts. Now, I’ve seen outfits talk plans without substance, but getting Tungsten Advisors on board...

Firehawk Defense Secures $150M, Valuation Hits $1.4B

Firehawk Defense Lands Major Funding Think about it—Firehawk Defense, a gutsy Dallas-based new-kid-on-the-block, just snagged a whopping $150 million in fresh funding. The news? Their valuation's now sitting pretty at $1.4 billion. Not peanuts, by any means. For a company in the artillery game, that's a blast of an announcement. They're predicting they'll become the big...

Step into Fear: Dead by Daylight in Moreno Valley

Immersive Horror in Moreno Valley Walking straight into the fog of your nightmares isn't for the faint-hearted, but that's the kind of thrill the Moreno Valley Museum & ArtSpace is serving up with its new Dead by Daylight Immersive Experience. Kicking off just in time for Halloween on October 30, this isn't your average stroll in a museum—it's a heart-pounding,...